about
Tamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsChemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathwayiTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells.Modification of marine natural product ningalin B and SAR study lead to potent P-glycoprotein inhibitorsClinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.Synthesis and characterization of DNA minor groove binding alkylating agentsClinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer.P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer modelThe use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.Transport processes of radiopharmaceuticals and -modulators.Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs.Low-density lipoprotein and ritonavir: an interaction between antiretrovirals and lipids mediated by P-glycoprotein.ABCG2/BCRP: Specific and Nonspecific Modulators.Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancerTransfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.Modulation of P-gp expression by lapatinib.Application values of 99mTc-methoxyisobutylisonitrile imaging for differentiating benign and malignant thymic masses.Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil.Design, synthesis, biological evaluation, NMR and DFT studies of structurally simplified trimethoxy benzamides as selective P-glycoprotein inhibitors: the role of molecular flatness.Studies on assessment methods of malignant ascites residue and changes of verapamil concentration in intraperitoneal perfusion chemotherapy.Cariprazine, A Dopamine D₂/D₃ Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
P2860
Q28084270-CD721F1B-9919-4B1A-B930-025FBAA676FEQ28480873-C815F52E-E8A9-44EC-AA2D-1093586CE213Q33960159-448D146B-E11D-42B9-9C61-0D5879DF5A3FQ34411540-18C03A73-1B94-467B-A6A9-0B1314637977Q34588085-0957D12E-7169-446B-9213-FF403A0E7E5FQ35057879-4F3CDBDF-35C1-4DE3-B008-538C8C5F7779Q36159042-A1D4919C-A8BF-4143-8F15-19E228C21CCCQ36746192-0BAB687A-E2AD-41AB-B01B-8C3A5C369F61Q37199799-325F1E31-9BCE-43E0-8046-140FCB936110Q37276052-319F4020-3325-48CC-86D8-EB7C198C9E64Q37438909-BB05ECBD-5F46-456A-ACC5-17A848D762BAQ37885468-6524A5AB-67F1-4249-86FB-82311D57B0B7Q38019607-67DE2197-EC74-4B6C-86BC-99B3899CFE30Q39013665-8EBE2766-2167-47F6-9FAF-FD6A7EB0EC1DQ39049159-638AFEC5-558C-4F51-8353-F0B4F1C9048CQ39153868-6FF690B5-DDA6-4CAF-8F71-48C10185817FQ39335333-DDBE7FF1-1893-49B2-B3FB-A61690CF59AFQ39635266-855DB8AB-13B2-49AD-88B0-28696F63F9FCQ39683562-8F2B4287-1D75-4A7C-AD29-130C7211D632Q41144176-094818EE-F7AA-42AE-A5AB-1CE0EFED1F58Q46716324-1784C97E-EBC4-430A-8997-6AB5612F8770Q51688651-C73BEC74-E4BF-44F4-BC3C-F57801166D44Q53501359-93B38A24-BB43-42FA-B5A3-A9FF7E516ABBQ58764275-ED705D1C-B47E-40EC-8BF1-72D58ABA748A
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Recent advances in the development of P-gp inhibitors.
@ast
Recent advances in the development of P-gp inhibitors.
@en
type
label
Recent advances in the development of P-gp inhibitors.
@ast
Recent advances in the development of P-gp inhibitors.
@en
prefLabel
Recent advances in the development of P-gp inhibitors.
@ast
Recent advances in the development of P-gp inhibitors.
@en
P1476
Recent advances in the development of P-gp inhibitors.
@en
P2093
Andreas Hilgeroth
Christiane Baumert
P304
P356
10.2174/1871520610909040415
P577
2009-05-01T00:00:00Z